ATHE - Alterity Therapeutics Limited

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3500
-0.0200 (-1.46%)
At close: 3:55PM EDT
Stock chart is not supported by your current browser
Previous Close1.3700
Open1.4100
Bid1.2500 x 1300
Ask1.7600 x 1100
Day's Range1.3500 - 1.4100
52 Week Range1.0900 - 2.9100
Volume1,986
Avg. Volume67,777
Market Cap19.858M
Beta (3Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • Business Wirelast month

    Initial Data for Alterity Therapeutics Phase 1 Clinical Trial Released at American Academy of Neurology Annual Meeting

    Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is today releasing interim clinical data of its Phase 1 clinical trial program for its investigative drug PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA. The Platform Presentation titled: A First in Human Study of PBT434, a Novel Small Molecule Inhibitor of α-Synuclein Aggregation is being delivered by David Stamler, MD, Chief Medical Officer & Senior VP Clinical Development.

  • Business Wirelast month

    Alterity Therapeutics Presents at the American Academy of Neurology Annual Meeting

    Alterity Therapeutics Limited, (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) will present clinical data from its lead drug candidate PBT434 at the American Academy of Neurology Annual Meeting in Philadelphia, USA, from 5-9th May 2019. Alterity will feature prominently at the Annual Meeting with a Platform Presentation on Sunday 5th May featuring data from the company’s Phase 1 clinical trial and a Poster Presentation featuring pre-clinical data on Thursday 9th May.

  • We're sorry this is all we were able to find about this topic.